SCHEMBL30490889

SCHEMBL30490889

COC(=O)CCCCCOCCOCCOCCCCCCOc1cccc(CNC(=O)OC(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GLS O94925 2/20 0.46
▸ EPHX2 P34913 3/20 0.45
▸ CYP3A4 P08684 1/20 0.42
▸ HDAC3 O15379 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC11 Q96DB2 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ CNR2 P34972 2/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ FAAH O00519 1/20 0.41
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25289842 1.00 GLS (0.46) GLSEPHX2CYP3A4HDAC3HDAC1
SCHEMBL24675764 0.95 GLS (0.47) GLSEPHX2CYP3A4HDAC3HDAC1
SCHEMBL24675795 0.95 GLS (0.47) GLSEPHX2CYP3A4HDAC3HDAC1
SCHEMBL24675890 0.91 GLS (0.45) GLSEPHX2CYP3A4HDAC3HDAC1
SCHEMBL25256244 0.90 CNR1 (0.45) CYP3A4CNR2CNR1CA12CA1
SCHEMBL30490842 0.87 GLS (0.43) GLSEPHX2CYP3A4FAAHCA12
SCHEMBL25249150 0.87 GLS (0.43) GLSEPHX2CYP3A4FAAHCA12
SCHEMBL24675927 0.86 GLS (0.44) GLSEPHX2CYP3A4FAAHCA12
SCHEMBL24675183 0.83 ROCK2 (0.49) GLSEPHX2CYP3A4CNR2FAAH
SCHEMBL24675514 0.82 CA12 (0.41) HDAC8CNR2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023129564-A9 DEGRADERS OF GRK2 AND USES THEREOF CYGNAL THERAPEUTICS, INC. (US) 2024-02-08 — — WO disclosed
WO-2023129564-A1 DEGRADERS OF GRK2 AND USES THEREOF CYGNAL THERAPEUTICS, INC. (US) 2023-07-06 — — WO disclosed
Send feedback